Polycythemia and Thrombocytosis

Polycythemia and thrombocytosis are hallmarks of myeloproliferative neoplasms, a group of bone marrow disorders characterized by the overproduction of blood cells. For you as a future clinician, mastering these conditions is crucial because they are not merely laboratory abnormalities; they carry a substantial risk of life-threatening thrombosis and can progress to bone marrow failure. A systematic, risk-stratified approach to evaluation and management is the cornerstone of preventing complications and improving survival.

Myeloproliferative Neoplasms: A Clinical Framework

Myeloproliferative neoplasms are clonal disorders of the hematopoietic stem cell that result in the excessive production of one or more mature blood cell lines. The three classic Philadelphia chromosome-negative MPNs are polycythemia vera, essential thrombocytosis, and primary myelofibrosis. Patients often present with symptoms related to increased blood viscosity or cell counts, such as headache, dizziness, pruritus (especially after a warm shower), or erythromelalgia (a burning pain in the hands and feet). A 58-year-old male presenting with a ruddy complexion, splenomegaly, and a platelet count of $900\times 10^9/L$ should immediately raise your suspicion for an underlying MPN. The initial evaluation hinges on distinguishing these clonal disorders from reactive causes, like smoking or iron deficiency for polycythemia, or inflammation for thrombocytosis, which requires a careful history, physical exam, and targeted laboratory testing.

The Central Driver: JAK2 Mutations

In most cases, the uncontrolled proliferation in MPNs is driven by acquired genetic mutations. The JAK2 V617F mutation is the most prevalent, found in approximately $95\%$ of polycythemia vera cases and $50-60\%$ of essential thrombocytosis and myelofibrosis cases. This mutation constitutively activates the JAK-STAT signaling pathway, leading to cytokine-independent growth and survival of hematopoietic cells. Understanding this molecular foundation is key because it informs both diagnosis and emerging therapies. Testing for the JAK2 mutation is now a critical diagnostic criterion; its presence confirms a clonal disorder. However, remember that a minority of ET and MF cases are associated with mutations in the calreticulin ($CALR$) or myeloproliferative leukemia virus ($MPL$) genes, underscoring the need for comprehensive molecular profiling in evaluation.

Polycythemia Vera: Controlling the Red Cell Mass

Polycythemia vera is defined by the autonomous overproduction of red blood cells, leading to elevated hemoglobin and hematocrit. The paramount goal of therapy is to reduce the risk of thrombotic events, which are the leading cause of morbidity and mortality. The cornerstone of treatment is phlebotomy, which rapidly decreases blood viscosity by removing red cells. The therapeutic target is to maintain a hematocrit below $45\%$, as studies demonstrate this threshold significantly reduces the rate of cardiovascular death and major thrombosis compared to a higher target. Alongside phlebotomy, low-dose aspirin is universally recommended to mitigate platelet-mediated thrombotic risk. For high-risk patients—defined by age over 60 or a prior thrombotic history—cytoreductive therapy with agents like hydroxyurea or interferon-alfa is added to phlebotomy to better control blood counts.

Essential Thrombocytosis: Stratifying Thrombotic Risk

Essential thrombocytosis is characterized by a sustained elevation in platelet count, typically greater than $450\times 10^9/L$. The central management principle is thrombotic risk stratification, which directly guides therapeutic decisions. High-risk patients include those over 60 years of age or with a history of thrombosis; these individuals require cytoreductive therapy (e.g., hydroxyurea, anagrelide) to lower platelet counts. For younger, low-risk patients who are often asymptomatic, observation or low-dose aspirin may be sufficient. A common clinical scenario is a 40-year-old female with a platelet count of $650\times 10^9/L$ and no other risk factors; here, the focus is on monitoring rather than immediate cytoreduction. It is critical to assess for the presence of the JAK2 mutation, as its presence in ET confers a higher baseline thrombotic risk, further refining stratification.

Myelofibrosis: Progression and Advanced Management

Myelofibrosis represents a more advanced MPN, where bone marrow fibrosis leads to progressive cytopenias and extramedullary hematopoiesis, often causing massive splenomegaly. It can arise de novo or evolve from PV or ET. The disease course is marked by marrow failure, leading to debilitating anemia, thrombocytopenia, and infection risk. Management is supportive and includes medications like ruxolitinib (a JAK inhibitor) to alleviate symptoms and reduce spleen size. For eligible patients with higher-risk disease, the only potentially curative option is allogeneic stem cell transplantation. This intensive procedure requires careful consideration of the patient's age, comorbidities, and disease risk score, highlighting the importance of early referral to a transplant center for assessment.

Common Pitfalls

1. Treating the Number, Not the Patient: Initiating cytoreductive therapy for thrombocytosis based solely on a high platelet count, without proper risk stratification, can expose low-risk patients to unnecessary drug toxicity. Always base treatment on age, thrombosis history, and molecular markers, not just laboratory values.
2. Inadequate Hydration During Phlebotomy: Performing phlebotomy in a patient with polycythemia vera without ensuring proper intravenous or oral hydration can lead to a sudden, dangerous drop in blood volume and acute renal injury. Always hydrate patients before and after the procedure.
3. Overlooking Disease Transformation: Failing to monitor for progression in PV or ET to myelofibrosis or acute leukemia is a critical error. Any patient with worsening cytopenias, increasing spleen size, or constitutional symptoms requires re-evaluation with a repeat bone marrow biopsy.
4. Misattributing Symptoms to Other Causes: Dismissing pruritus, night sweats, or early satiety as benign or age-related without considering an underlying MPN can delay diagnosis for years. In any patient with unexplained blood count abnormalities, include MPNs in your differential.

Summary

• Myeloproliferative neoplasms, including polycythemia vera, essential thrombocytosis, and myelofibrosis, are clonal disorders driven predominantly by JAK2 mutations, which confirm the diagnosis and influence risk.
• The management of polycythemia vera centers on phlebotomy to maintain a hematocrit below $45\%$, combined with low-dose aspirin and cytoreduction for high-risk patients to prevent thrombosis.
• Treatment for essential thrombocytosis is guided by thrombotic risk stratification, with cytoreductive therapy reserved for high-risk individuals (age >60 or prior thrombosis).
• Myelofibrosis is a progressive disease that can lead to marrow failure; allogeneic stem cell transplantation remains the sole curative option and must be considered for eligible, higher-risk patients.
• A systematic evaluation to rule out reactive causes and ongoing monitoring for disease progression are essential components of comprehensive MPN care.